|Bid||171.75 x 300|
|Ask||172.25 x 200|
|Day's Range||170.58 - 173.47|
|52 Week Range||152.16 - 201.23|
|PE Ratio (TTM)||63.78|
|Forward Dividend & Yield||5.28 (3.08%)|
|1y Target Est||N/A|
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday. The 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects. "This is a trial in really difficult to treat patients," professor Uwe Reuter, trial investigator and managing medical director at Charité Universitätsmedizin in Berlin, told Reuters in a telephone interview.
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.
AbbVie (ABBV) generated revenue of $7.7 billion in 4Q17 and $6.8 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~11% growth quarter-over-quarter. AbbVie reported revenue of $28.2 billion in fiscal 2017 and $25.6 billion in fiscal 2016, representing ~10% YoY growth.
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries. Amgen’s Repatha is a human monoclonal antibody that inhibits proprotein convertase kexin type nine (or PCSK9). The drug has been approved in more than 50 regions, including the United States, Japan, Canada, and the European Union.
In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.
On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.
Amgen (AMGN) is a biotechnology company with headquarters in Thousand Oaks, California. Amgen discovers, develops, and delivers drugs for various therapeutic areas, including cardiovascular, neuroscience, and oncology.
Amgen Inc will build a $165 million next-generation biopharmaceutical plant adjacent to its West Greenwich, Rhode Island manufacturing campus, the state governor's office told Reuters on Tuesday. The plant will use Amgen's new flexible and reconfigurable technology, part of the company's ongoing efforts to control costs. Amgen, headquartered in Thousand Oaks, California, said in January it would locate the new plant in the United States, due in part to a lower effective tax rate stemming from U.S. tax reform.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $13.67 billion.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions....
AbbVie put another brick in the wall surrounding key moneymaker Humira early Thursday, announcing a deal that prevents Biogen from launching a copycat in the U.S. until June 2023.
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
The biotech space wasn't immune to the broader market sell-off in March, although the degree of negativity was less pronounced among defensive biotech stocks. Rising demand for drugs, as the population ...